Abstract
Introduction
Buprenorphine (BUP) is a high af nity partial mu-opioid agonist with a long duration of action (Rance & Dickens, 1978; Bickel & Amass, 1995) . BUP is comparable to methadone in retaining opioid-dependent patients in maintenance and detoxi cation trials (Bickel et al., 1988a; Johnson, Jaffe & Fudala, 1992; Ling, 1996 , but see Kosten et al., 1993) .
BUP also has some advantages over methadone. Notably, BUP has a ceiling level on agonist activity limiting adverse reactions, such as respiratory depression, at very high doses (Jasinski, 1977; Bickel et al., 1988b; Lange et al., 1990; Walsh et al., 1995) . Because large doses do not result in increased opioid effects and the drug dissociates slowly from the opiate receptor, BUP can be administered at high doses and relatively long inter-dosing intervals. These properties may render BUP bene cial over methadone, which requires daily administration.
In studies using double-blind procedures, we have shown that increasing the liquid-based BUP dose to three or four times the maintenance dose (up to 32 mg/70 kg) prevents clinically signi cant withdrawal symptoms for a 96-hour period (Amass et al., 1994; Petry, Bickel & Badger, 1999; Bickel et al., 1999) . Acceptability of every-fourth-day dosing regimens was also demonstrated. When given the options of daily dosing, double doses followed by a day off from the clinic, triple doses followed by two days off, or quadruple doses followed by three days off, 46% of participants chose to be dosed every fourth day (Petry, Bickel & Badger, 2000) .
Given the acceptability of this every-fourthday dosing regimen, the present studies sought to evaluate the effects of extending the interdosing interval to every fth day. In Study I, we administered quintuple the daily maintenance dose every 5 days and compared this dosing regimen to daily dosing as well as to triple doses every three days. In this study, all doses were provided under double-blind procedures, and opioid withdrawal symptoms were rated daily by participants and observers. In Study II, we provided these same three dosing regimens under open-dosing procedures and then evaluated participants' preferences for them.
Study 1: Methods Participant
Twenty-ve opioid-dependent outpatients (17 male, eight female) enrolled in the study, and 18 completed it (11 male, seven female). Inclusion criteria were $ 18 years old, good health and DSM-III-R criteria for opioid dependence. Pregnancy and evidence of active psychosis, manicdepressive illness or serious medical illness (liver or cardiovascular disease) were exclusion criteria. The study was approved by the Institutional Review Board, and participants provided written informed consent.
Participants' mean age was 35 years (range 22-51), and mean weight was 82 kg (range 50-112). On average, participants reported using opioids for 12 years (range 1-31) and spending $360 (range $0-$1,500) per week on opioids. Ninety-ve per cent were intravenous drug users. Weekly pregnancy tests were conducted for females and were negative throughout the study.
General procedures
Study continuation and compensation ($50/ week) were contingent on attendance for all doses and opioid abstinence. Participants attended the clinic at the same time each day to facilitate appropriate dosing schedules. Opioid abstinence was required to ensure that changes in subjective effects were related to dosing regimens provided and not resultant from other opioid use. Participants received one 60-minute counseling session weekly.
Urine specimen monitoring
Opioid abstinence was con rmed via urinalysis testing conducted thrice weekly, prior to medication administration. Urine samples were collected under staff observation and analyzed onsite for opioids (methadone, propoxyphene and opioids) via Enzyme Multiplied Immunoassay Technique (Syva Corp., San Jose, CA, USA). Barbiturate, benzodiazepine, marijuana and cocaine use was assessed once weekly on a random basis using this testing technique. When participants submitted an opioidpositive sample no medication was provided that day, and they returned to the clinic the next day for dosing. Data collected in the days prior to an opioid-positive sample (range 1-3 days) were omitted from analyses. Participants continued in the study provided the subsequent result indicated no further opioid use (Petry et al., 1999) . Study participation was terminated upon receipt of a second positive sample.
Medication administration
All BUP doses were masked for taste with peppermint and 1 ml of Bitrex granules (6 l g/ml; Macfarlane-Smith Ltd., Edinburgh, UK). Participants swished this peppermint solution in their mouth for 30 seconds and discarded it before receiving medication.
BUP hydrochloride (Reckitt & Colman, Hull, England, UK) was prepared as a stock concentration of 16 mg/ml in 35% ethanol (vol/vol Participant's maintenance doses were determined during the rst week of study participation. Participants initially were placed on a 2 mg/70 kg dose at intake, and on a 4 mg/70 kg dose on day 2. If objective withdrawal symptoms (see below) were evident on days 3-7, the dose was increased to 8 mg/70 kg. In total, eight study completers received the 4 mg/70 kg daily maintenance dose, and 10 received the 8 mg/70 kg daily maintenance dose.
Laboratory safety session
After dose stabilization, the daily maintenance dose was administered for 10 days. Participants then participated in a 7-hour laboratory safety session (see Petry et al., 1999 for details) in which they were exposed to ve times their daily maintenance dose of BUP (20 or 40 mg/70 kg) in a controlled setting to ensure safety of and tolerance to this dose. No participants experienced adverse opioid agonist effects.
Exposure phase
For 4 days after the safety session, participants received their daily maintenance dose under double-blind procedures. On days 5-7, participants again received a maintenance dose daily, but for these 3 days the dose was provided under open-dosing procedures, and participants were told they were receiving their maintenance dose at dispensation. These 3 days were included to allow participants to experience how they felt when they knew they were receiving their maintenance dose. Following this open-dosing exposure, they received daily maintenance doses for 10 days under double-blind procedures.
Experimental conditions
After the baseline phase described above, exposure to the three dosing regimens commenced. Participants received the regimens in a random order: maintenance dose daily, triple maintenance dose every third day and quintuple maintenance dose every fth day. Each regimen was kept in effect for ve repetitions, such that the daily regimen was in effect for 5 days, the triple-every-third-day regimen for 15 days and the quintuple-every-fth-day regimen for 25 days. After receiving all three regimens, participants received daily maintenance doses for 5 days. Following study completion, they could participate in other studies or a detoxi cation.
Outcome measures
Observer-ratings. Research staff (blind to the treatment conditions) completed an observerrating scale before dispensing medication. The staff rated participants on a scale of 0 (not at all) to 9 (severe) on signs of opioid withdrawal (goose esh, sweating, restlessness, tremor, lacrimation, nasal congestion and yawning) and agonist activity (skin itching, vomiting, sedation, nodding and soap-boxing/nodding). The observer-rating scale was based on Addiction Research Center withdrawal scales (Himmelsbach, 1939; Jasinski, Pevnick & Grif th, 1978) .
Participant ratings. Each day before receiving medication, participants completed computerized versions of the adjective-rating scale (ARS), visual-analog scales (VAS) and the Addiction Research Center Inventory (ARCI) short form. Participants were instructed to respond to questions according to their experiences over the past 24 hours.
The ARS (Bickel et al., 1988a) consists of 32 opioid withdrawal and drug symptoms. Participants rated each item according to a 0 (none) to 9 (severe) scale, and means across all items are shown. Items in the opioid withdrawal scale were: muscle cramps, depressed/sad, painful joints, yawning, hot/cold ashes, trouble getting to sleep, sick stomach, runny nose, poor appetite, weak knees, abdominal cramps, tense/jittery, excessive sneezing, irritable, watery eyes and tful sleep. Items in the opioid effects scale were: drug effect, loaded/high, rush, ushing, sweating, nodding, dry mouth, stomach turning, itchy skin, relaxed, coasting/spaced out, talkative, pleasant sickness, drive, nervousness and drunken.
The VAS (Preston, Bigelow & Liebson, 1988; Petry et al., 1998) items were: High, Drug, Good, Like, Bad and Sick. Participants made a mark along a 100-mm line, anchored at each end by "not at all" and "severe". Responses were converted to a 100-point scale.
The ARCI short form (Martin et al., 1971; Jasinski, 1977) consisted of 49 true/false items. Five scales assessed sedation, dysphoria, euphoria and stimulation: pentobarbitol, chlorpromazine, alcohol group (PCAG), lysergic acid diethylamide (LSD), morphine benzedrine group (MBG), benzedrine group (BG) and amphetamine (A).
A dose identi cation measure was also used, in which participants indicated whether they received placebo or a maintenance, triple, or quintuple dose the prior day. Data were scored as identi cation of placebo or higher than the maintenance dose. Pupil diameter was determined before dispensing medication from photographs taken with a Polaroid camera at 2 3 magni cation at 1 ft-c of ambient illumination (Jasinski & Martin, 1967) .
Data analyses
Data obtained during the triple and quintuple dosing regimens were partitioned into individual components for analyses, e.g. hours since last active dose. In total, nine conditions were obtained: 24-hour post-maintenance doses, 24-hour post-triple doses, 48-hour post-triple doses, 72-hour post-triple doses, 24-hour post-quintuple doses, 48-hour post-quintuple doses, 72-hour post-quintuple doses, 96-hour postquintuple doses and 120-hour post-quintuple doses. For the study completers, repeated measures analyses of variance were conducted with one within-subject factor (condition, with nine levels) and one between-subjects factor (maintenance dose, with two levels-4 or 8 mg/ 70 kg). When the overall F test corresponding to conditions was signi cant, Dunnett's procedure was used to determine whether measures obtained during the eight experimental conditions differed from the 24-hour post-maintenance dose condition. Data from participants who withdrew or were discharged from the study are not included in these analyses because they did not complete all three dosing regimens. Analyses were performed using SAS, and statistical signi cance was determined using a 5 0.05, twotailed.
Descriptive data are presented for percentage of urine samples that were positive for opioids and other drugs across the dosing regimens. Because urine samples were obtained thrice weekly, we cannot assess the exact day of drug use. Therefore, data are shown across entire dosing regimens (% positive during maintenance, triple, and quintuple dosing regimens). Because submission of opioid-positive samples resulted in study termination, urinalyses data are presented from all participants enrolled, including non-completers.
Study 1: Results

Retention
Of the 25 participants enrolled in this study, 72% (n 5 18) completed it. Two participants requested detoxi cation because they had dif culties with transportation or daily attendance. One stopped attending the program while receiving quintuple doses. Another failed to attend the clinic during baseline and again during the quintuple dosing regimen, and another during the maintenance as well as during the quintuple dosing regimens. One participant was discharged for submitting opioid-positive samples during the maintenance and quintuple dosing regimens, and the nal participant was discharged for ghting in the clinic. Data from one participant who completed the study (a female on 8 mg/70 kg for a maintenance dose) are not included in the analyses because computer malfunction resulted in substantial missing data.
Participant and observer ratings of drug effects
Signi cant effects of BUP dose (4 vs. 8 mg/ 70 mg) were noted on only one of the 18 outcome variables-subjective ratings of withdrawal on the ARS, F(1,15) 5 6.95, p 5 0.02. Signicant BUP dose by condition effects were not found on any of the outcome data. Therefore, Table 1 shows means and SEMs on the outcome measures collapsed across BUP maintenance doses (4 and 8 mg/70 kg).
Signi cant differences were noted across the conditions on the majority of outcome variables including: ARS subjective reports of withdrawal [F(8,120) For outcome measures in which signi cant overall differences were found across the conditions, Dunnett's procedure compared data obtained 24 hours following maintenance doses to that obtained at each of the other eight conditions. These results are denoted by asterisks and bold text in Table 1 . Some measures of opioid withdrawal rose as hours since the last active dose increased (ARS withdrawal scores, and Bad and Sick scores on the VAS). Sedation and dysphoria scores on the ARCI also rose in the 96-120 hours following a quintuple dose compared to 24 hours after maintenance dosing. Some drug-like effects decreased as hours since the active doses increased (e.g. reductions in BG and A scales of the ARCI). In addition, scores on the VAS High scale rose, and scores on the ARS withdrawal scale decreased, 24 hours after quintuple compared to 24 hours after maintenance doses.
The percentage of times participants guessed they had received a placebo [F(8,120) 
Urinalysis testing
Urinalysis testing revealed that 2% of urine samples were positive for opioids during the maintenance dosing regimen, 5% during the triple dosing regimen, and 5% during the quintuple dosing regimen. The percentage of urine samples testing positive for other drugs also are shown in Table 2 ; they did not vary systematically across conditions.
Study 1: Discussion
Two main ndings emerged from this study. First, increases in opioid agonist effects following administration of quintuple the maintenance dose were noted on only one outcome measure. On the "High" scale of the VAS, responses increased from an average of 8 during daily maintenance dosing to a mean of 14 in the 24 hours after a quintuple dose. Although this increase was statistically signi cant, it may not be clinically meaningful. The VAS ranks subjective reports along a 100-point scale and therefore a score of 14 is still low. While higher agonist ratings may have occurred had we measured subjective reports 1-2 hours (rather than 24 hours) post-quintuple dosing, no objective or subjective indicators of opioid agonist activity were noted when participants received ve times their maintenance doses during the laboratory safety session. This evidence, in conjunction with the fact that signi cant increases were not noted on any other subjective indices of opioid agonist activity following quintuple doses, suggests that opioid agonist activity was minimal following quintuple doses. On the ARS withdrawal scale, signi cant decreases in withdrawal were noted 24 hours following quintuple doses compared with 24 hours following maintenance doses. Thus, rather than inducing opioid-like effects, larger BUP doses may abate chronic feelings of withdrawal.
Secondly, signi cant increases in withdrawal symptoms emerged 96 to 120 hours following administration of quintuple doses. Signi cant differences across dosing conditions were found on 10 of the 13 subjective report measures, with Dunnett's procedures con rming that many of these effects were related to increased withdrawal symptoms 96-120 hours after quintuple doses. Even physiological manifestations of opioid withdrawal occurred, with pupil diameter increasing signi cantly 120 hours following quintuple doses. In contrast, no increases in opioid withdrawal were found up to 72 hours after triple BUP doses. These data replicate and extend our previous ndings regarding less than daily BUP dosing regimens. In a double-blind study examining up to every-fourth-day dosing regimens with quadruple maintenance doses (Petry et al., 1999) , we found that subjective reports of opioid withdrawal increased as time since last active dose increased. However, when quadruple, every-fourth-day dosing was provided using opendosing procedures (Petry et al., 2000) , signi cant increases in subjective reports of opioid withdrawal were noted on only two of the 13 subjective report measures. Nearly half the participants selected quadruple-every-fourth-day dosing over daily or any other less-than-daily dosing option. Therefore, the purpose of Study II was to evaluate whether increased opioid withdrawal symptoms emerged when these dosing regimens were administered under open and choice dosing conditions.
Study II: Methods
Participants
Seventeen patients (12 male and ve female) enrolled in this study, and 15 (11 male and four female) completed it. The same inclusion criteria were used, and participants had similar demographic characteristics as in Study 1.
General methods
The general methods were similar to those described in Study I, with only a few exceptions as described below. Dose induction and stabilization procedures were the same as in Study I. In total, six study completers received the 4 mg/ 70 kg daily maintenance dose, and nine received the 8 mg/70 kg maintenance dose. A laboratory safety session was also provided, following which participants received 10 days of daily maintenance dosing and were told each day that these doses were their daily maintenance doses.
For the open-exposure phase of Study II participants received, in a random order, each of the three dosing regimens: daily maintenance dosing, triple-every-third-day dosing, and quintupleevery-fth-day dosing. The daily dosing regimen was in effect for 5 days, and the other two regimens were in effect for 3 repetitions of each regimen.
Following the 29-day open-dosing exposure phase, participants received daily maintenance doses for 5 days. They then were presented with choice conditions: (1) daily maintenance doses or triple doses every third day; (2) daily maintenance doses or quintuple doses every fth day; and (3) triple doses every third day or quintuple doses every fth day. Each choice was kept in effect for 15 days such that whatever dosing regimen was selected was administered for the next 15 days. The three choice conditions were presented in a random order, and participants were presented with each of the three choice conditions throughout a 45-day period. At the end of the study, participants received maintenance doses daily for 5 days and were then offered the opportunity to participate in other studies or receive a detoxi cation.
Because participants did not attend the clinic daily in Study II, some minor changes were made to the urine specimen testing procedures. Instead of Monday-Wednesday-Friday submission of specimens, participants provided samples prior to medication administration at least two times a week, and often three times a week. In addition, participants in Study II were also telephoned at home on a random basis (at least once for each participant) during every-fth-day dosing. When called for a random specimen, participants were required to come to the clinic within 24 hour and submit a urine sample. Failure to submit a specimen was considered a positive sample. Only one participant, who subsequently withdrew from the study, failed to submit a random specimen during the quintuple dosing regimen.
Dependent measures for the open-dosing phase of Study II were similar to those described in Study I, with the exception that data were only collected prior to the receipt of each dose: 24-hour post-maintenance doses, 72-hour posttriple doses and 120-hour post-quintuple doses.
Participants were instructed to report their experiences since the time of their last active dose. Dose identi cation and pupil diameter data were not collected in Study II.
The dependent measure for the choice phase was the percent of participants choosing the dosing schedule requiring the least clinic attendance.
Data analysis
For the open-exposure phase in Study II, comparisons of subjective and observer ratings in the three dosing regimens were performed using repeated measures analysis of variance corresponding to a three-period, within-subjects design. A participant's daily maintenance dose (4 or 8 mg/ 70 kg) was considered as an additional factor. Dunnett's procedure was used to compare measures obtained during the daily maintenance dosing regimen to each of the other less than daily regimens when the overall F was signi cant.
For the choice phase of Study II, descriptive data are shown for percentage of participants who chose the dosing schedule requiring the least attendance in the 3 conditions.
Study II: Results
Retention. Of the 17 enrolled participants, 88% (n 5 15) completed the study. One participant requested withdrawal after failing to submit a random urine specimen during open-exposure to quintuple doses, and a second was discharged for submission of opioid-positive urine samples during baseline dosing as well as during the quintuple dosing regimen.
Participant and observer ratings of drug effects
The means obtained on the various outcome measures are shown in Table 3 . Repeatedmeasures ANOVA revealed signi cant differences among the three dosing regimens on the majority of indices of subjective and observerrated drug and withdrawal effects. Signi cant differences were noted in observer-rated withdrawal effects [F(2,26) On these variables, Dunnett's procedure was used to compare data obtained during the maintenance dosing regimen to that obtained during each of the other two dosing regimens. These results are shown in Table 3 . Generally, these analyses indicated that withdrawal scores (e.g. ARS withdrawal scores and VAS Sick scores) increased during the less frequent dosing regimens and drug-like effects (e.g. VAS Drug and Good scores) decreased. On the ARCI, scores of sedation and dysphoria (PCAG, LSD) increased in the quintuple dosing regimen compared to the maintenance dosing regimen, while scores of euphoria and stimulation (MBG, BG) decreased in the less-frequent dosing regimen. Figure 1 shows the percentage of participants choosing the dosing regimen with the least clinic attendance across the three choice conditions. When daily maintenance dosing was paired with triple-every-third-day dosing, 67% of the 15 participants (n 5 10) chose to attend the clinic less than daily. When daily maintenance dosing was paired with quintuple-every-fth-day dosing, 27% (n 5 4) chose to be dosed every fth day. Only one participant (7%) chose quintupleevery-fth-day dosing over triple-every-third-day dosing.
Choice data
Urinalysis testing
During the open-dosing exposure phase, 2% of urine samples were positive for opioids during maintenance dosing, 1% during triple dosing and 7% during quintuple dosing. During the choice phase, 2% of the urine samples were opioid positive when participants chose maintenance dosing, 1% were positive when participants chose triple dosing and 4% were positive when participants chose quintuple dosing. Other drug use across the open-and choice-dosing phases of the study are shown in Table 4 as well.
Study II: Discussion
The results of Study II replicated those found in Study I. During the quintuple dosing regimen, observer ratings of opioid withdrawal increased signi cantly compared to daily maintenance dosing, and subjective reports changed signi cantly on nine of the 13 subjective outcome variables. Moreover, in the choice phase of Study II, less than one-third of the participants selected quintuple, every-fth-day dosing over daily dosing, and less than 10% selected the everyfth-day-dosing regimen over the every-thirdday-dosing regimen.
General discussion
In previous studies (Petry et al., 1999 (Petry et al., , 2000 , we found that BUP administered as infrequently as every 4 days results in minimal withdrawal symptoms and that the majority of participants prefer to be dosed according to less than daily dosing regimens. The present studies were an extension of these ndings to examine whether the interdosing interval can be extended from 4 to 5 days. The results suggest that quintuple, every-fthday-dosing regimens are not well tolerated or preferred among opioid-dependent outpatients. By 120 hours after a quintuple dose, signi cant increases in opioid withdrawal symptoms were noted on a variety of outcome measures in both the blind-dosing study as well as the open-dosing study. Only one of 15 participants (7%) elected to be dosed every-fth-day rather than everythird day. Several issues that may bear upon the interpretation of these ndings are discussed.
Despite the increase in opioid withdrawal symptoms noted during every-fth-day dosing, urine testing results were generally negative for opioids, suggesting that participants were able to tolerate this dosing regimen. Limitations of these results, however, include that participants were compensated to remain opioid abstinent. To continue in these studies, participants had to maintain opioid abstinence and be compliant with a variety of clinic policies, including frequent and random urine testing procedures. Compared to participants in this study, opioiddependent outpatients who are generally less compliant may be even less likely to tolerate this dosing regimen, and they may experience more severe withdrawal symptoms and use more illicit opioids when exposed to less frequent BUP dosing regimens.
In both studies, urine sample testing revealed barbiturate and cocaine use was relatively low across the dosing regimens. In contrast, marijuana and benzodiazepine use was prevalent in these participants, and the use of these drugs generally remained high across the dosing regimens. Although other drug use may have affected subjective responses on the outcome measures, mandating abstinence from all drugs of abuse is very dif cult among opioiddependent outpatients. Because other drug use did not vary systematically across regimens, we expect that it did not greatly in uence outcomes.
The only apparent change in drug use across regimens was that benzodiazepines use was lower (8% positive) when participants chose quintuple every-fth-day dosing regimens during the choice phase of Study II, compared to rates of benzodiazepine use during the other choice-or open-dosing regimens (29-53% positive). Individual analysis of these data indicated that the participants who frequently used benzodiazepines did not select the quintuple dosing regimen and, therefore, rates of benzodiazepine use were arti cially lower among those who selected this dosing regimen.
In summary, data from these studies suggest that these participants, while maintaining opioid abstinence, experienced moderate to severe opioid withdrawal symptoms when the interdosing interval was extended to 5 days. This increase in withdrawal was noted whether doses were provided in blind-or open-dosing conditions. The vast majority of participants chose not to be dosed according to quintuple-every-fth-day dosing regimens. Therefore, twice weekly BUP dosing regimens (e.g. quadruple doses on Mondays and triple doses on Fridays) may be the maximal extension of interdosing intervals.
Although our previous studies (Petry et al., 1999 (Petry et al., , 2000 suggest that twice weekly BUP dosing may be feasible, future research needs to replicate these ndings under non-laboratory study conditions. For example, whether patients maintained on higher daily maintenance doses of BUP (e.g. 12 mg/day) also prefer every-fourth-day dosing needs to be evaluated. Subsequent studies may also examine the acceptance of twice weekly dosing schedules when the BUP tablet (or BUP-naloxone tablet) are provided, and when doses are not in uenced by body weight. If absorption of BUP is impaired when multiple tablets are provided, then the duration of action may be even shorter than reported in this study. Because agonist effects were not noted in this study or another in which sextuple the maintenance dose was provided (Gross et al., in press ), even higher doses may be indicated to reduce withdrawal in some patients. Our studies generally provide brief exposure to the regimens. Under more chronic dosing conditions, withdrawal symptoms may be more likely to occur. Finally, individual difference in response to less-frequent dosing intervals may emerge, such that some patients may not respond well to even everyother-day BUP dosing.
Although the present studies nd that the interdosing interval cannot be extended to every fth day using sublingual doses, the feasibility of a twice-weekly BUP dosing schedule (Petry et al., 1999 (Petry et al., , 2000 may allow physicians to serve a greater number of patients without the risk of diversion associated with take-home medications. The feasibility of less-than-daily BUP dosing options has resulted in pilot projects evaluating the ef cacy of BUP maintenance from physician of ces (O'Connor et al., 1998) . Future studies may provide more information regarding the effectiveness of these procedures in the treatment of opioid dependence.
